Skip to main content

Dementia With Lewy Bodies Risk Down With α-1 Adrenergic Receptor Antagonists

Medically reviewed by Carmen Pope, BPharm. Last updated on June 20, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, June 19, 2024 -- Men taking α-1 adrenergic receptor antagonists terazosin, doxazosin, and alfuzosin (Tz/Dz/Az) seem to have a lower risk for dementia with Lewy bodies (DLB), according to a study published online June 19 in Neurology.

Alexander Hart, M.D., M.P.H., from the University of Michigan in Ann Arbor, and colleagues used a new-user active comparator design in the Merative Marketscan database to identify men with no history of DLB who were newly initiated on Tz/Dz/Az or two comparator medications (α-1 adrenergic receptor antagonist tamsulosin or 5α-reductase inhibitor [5ARI]) to examine the potential neuroprotective effects of Tz/Dz/Az.

The researchers found that the risk for developing DLB was lower for men who were newly started on Tz/Dz/Az than those taking tamsulosin or 5ARI (hazard ratios, 0.60 and 0.73, respectively), while the risk was similar for men taking tamsulosin versus 5ARI. The results were robust to sensitivity analyses.

"More research is needed to follow people over time and determine whether there is a cause-and-effect relationship here, but it is promising to think that these drugs could have a protective effect on this disease that will likely affect a larger number of people as the population ages," coauthor Jacob E. Simmering, Ph.D., of the University of Iowa in Iowa City, said in a statement.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted June 2024

Read this next

Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care

TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...

Emergence of Psychosis in Alzheimer Disease Linked to Elevations in p-tau181

MONDAY, July 1, 2024 -- For individuals with Alzheimer disease (AD), the emergence of psychosis is associated with elevations in levels of plasma tau phosphorylated at threonine...

Lower Cognitive Function in Adolescence Linked to Stroke Risk

FRIDAY, June 28, 2024 -- Lower cognitive function in adolescence is associated with increased risk of early-onset stroke, according to a study published online June 27 in the...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.